Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Leerink Swann lifted their FY2019 earnings estimates for shares of Sarepta Therapeutics in a report released on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $0.47 for the year, up from their prior forecast of $0.37. Leerink Swann currently has a “Buy” rating and a $60.00 price objective on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. The business’s quarterly revenue was up 350000.0% compared to the same quarter last year. During the same period last year, the company earned ($1.19) EPS.

TRADEMARK VIOLATION WARNING: “FY2019 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Leerink Swann (SRPT)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/fy2019-eps-estimates-for-sarepta-therapeutics-inc-increased-by-leerink-swann-srpt.html.

Other equities research analysts also recently issued research reports about the stock. Piper Jaffray Companies set a $43.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 18th. Credit Suisse Group lifted their price target on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research note on Thursday. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $76.00 price target on shares of Sarepta Therapeutics in a research note on Thursday. Nomura reaffirmed a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $101.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of “Buy” and an average target price of $61.58.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 2.01% during trading on Thursday, reaching $45.79. The company had a trading volume of 3,052,438 shares. The stock has a 50 day moving average price of $38.96 and a 200-day moving average price of $34.02. The company’s market capitalization is $2.95 billion. Sarepta Therapeutics has a 52-week low of $25.47 and a 52-week high of $63.73.

In related news, CEO Douglas S. Ingram bought 47,058 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the transaction, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Alexander Cumbo sold 5,918 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at approximately $934,513. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock valued at $3,224,208 in the last three months. Insiders own 9.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Prentiss Smith & Co. Inc. increased its position in shares of Sarepta Therapeutics by 772.2% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $127,000. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 150.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the last quarter. Finally, Edge Wealth Management LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth about $175,000. 65.43% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.